Gates Foundation Funds AI for Tuberculosis Research
The grant supports DaltonTx in creating open-access AI tools to accelerate drug discovery for tuberculosis.
Updated on Oct. 15, 2026 in Diseases — General
Live Poll
Should private AI developers prioritize making their drug discovery tools open-access for global health research?
DaltonTx has secured a grant from the Gates Foundation to develop AI models aimed at identifying new tuberculosis treatments. The initiative seeks to streamline the drug discovery process by targeting hundreds of Mycobacterium tuberculosis genes.
Why it matters
Tuberculosis remains a significant health burden in low- and middle-income nations, where there is an urgent need for faster, more cost-effective development of new therapies.
The project uses machine learning and physics-based modeling to analyze hundreds of essential Mycobacterium tuberculosis genes. This evidence-based approach aims to reduce the time and costs typically associated with identifying chemical starting points for new therapies.
The players
DaltonTx
This organization specializes in leveraging advanced computational methods for drug discovery and pharmaceutical research.
Gates Foundation
Based in Seattle, Washington, this philanthropic organization funds global health and development initiatives aimed at reducing inequality.
Ersilia
This non-profit organization provides open-source AI tools and resources to researchers to promote equitable access to scientific innovation.
The details
Through a partnership with the non-profit Ersilia, DaltonTx will distribute open-access models, workflows, and datasets via the Ersilia Model Hub. The project also incorporates specialized training and workshops for researchers based in the Global South.
Timeline
October 15, 2026: DaltonTx announced the receipt of the grant.
The Big Picture
This project utilizes the Ersilia Model Hub to share its research findings with a global audience. This approach reflects a growing movement in the scientific community toward open-source drug discovery, marking a departure from traditional closed-access pharmaceutical data silos.
By lowering the cost and time requirements for drug discovery, this project could eventually lead to more affordable and accessible treatments for infectious diseases. Researchers in the Global South will benefit directly from new training opportunities and the ability to utilize advanced AI models.
The takeaway
Using artificial intelligence in drug discovery offers a promising pathway to address diseases that have historically been underfunded. Scientists and global health advocates can utilize these open-access datasets to collaborate on solutions that were previously inaccessible due to high resource demands.
Further reading
For more context on infectious disease research, visit the Diseases — General section.
Live Poll
Should private AI developers prioritize making their drug discovery tools open-access for global health research?
